Accelerating the development of biomarkers for drug safety
Subtitle: workshop summary
By: Steve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
Contributors: Olson, Steve, 1956-; Robinson, Sally; Giffin, Robert B.
Publisher: National Academies Press
Published: 2009
Place of publication: Washington, D.C
Language: eng
Number of pages: 83
ISBN-13: 9780309131247
Subjects: Biochemical markers; Safety measures; Pharmacological Biomarkers; Congresses; Drugs; Testing
Description: "Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held  'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website.
Notes: Errata sheet inserted.

Includes bibliographical references.

Also available online.
Table of contents: title: Overview Of key issues; title: Cardiac safety biomarkers; title: Assessing and predicting kidney safety; title: Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials; title: Future considerations.